Browse Studies — Arctuva

Phase 3

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Axatilimab and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease (AXemplify-357)

This study will be conducted to compare the efficacy of axatilimab versus placebo in combination with corticosteroids as initial treatment for moderate or seve…

Chronic Graft-versus-host-disease

Estimated

~$10 – $8,750

Incyte CorporationNCT06585774

Phase 2

A Phase 2, Randomized, Open-Label Study of Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft-Versus-Host Disease After at Least 2 Prior Lines of Systemic Therapy (AGAVE-256)

This study will be conducted to compare Axatilimab Versus Best Available Therapy in Pediatric Participants With Chronic Graft Versus Host Disease After at Leas…

Chronic Graft-versus-host-disease

Estimated

~$10 – $8,750

Incyte CorporationNCT07124078

Phase 2

AGAVE-201, A Phase 2, Open-label, Randomized, Multicenter Study to Evaluate the Efficacy, Safety and Tolerability of Axatilimab at 3 Different Doses in Patients With Recurrent or Refractory Active Chronic Graft Versus Host Disease Who Have Received at Least 2 Lines of Systemic Therapy

This is a Phase 2 study to evaluate the efficacy, safety, and tolerability of axatilimab at 3 different dose levels in participants with recurrent or refractor…

Chronic Graft-versus-host-disease

Estimated

~$10 – $8,750

Syndax PharmaceuticalsNCT04710576

Observational

Impact of Exercise on the Complications of Corticosteroids in Patients With Graft-Versus-Host Disease Following Allogeneic Stem Cell Transplantation: the RESTART Trial

This study is about determining if an aerobic and resistance exercise intervention is feasible in patients diagnosed with acute or chronic GVHD (Graft-Versus-H…

Graft Vs Host DiseaseAcute-graft-versus-host DiseaseChronic Graft-versus-host-disease

Estimated

~$10 – $7,500

Dana-Farber Cancer InstituteNCT05236062